Cancer Biologics Market Growth

Cancer Biologics Market Growth is Anticipated at CAGR of 8.9% till 2035 | Roots Analysis

According to a recently published report by Roots Analysis, the growing prevalence of cancer along with increased demand for targeted and highly effective personalized medicine, is driving the cancer biologics market growth.

Cancer Biologics Industry Overview

The global cancer biologics market size is estimated to reach USD 442 billion by 2035, representing a higher CAGR of 8.9% in the forecast period.

Cancer biologics are advanced therapeutic agents, which are derived from living systems and purified to target specific molecular pathways involved in tumor growth and survival. Recent advancements in various biologics, including monoclonal antibodies and immune checkpoint inhibitors, have revolutionized cancer treatment by improving precision and reducing damage to healthy tissues. Moreover, innovations such as artificial intelligence-driven drug discovery and cell-based cancer therapies have further enhanced the effectiveness and accessibility of cancer biologics. As a result, biologics have become an indispensable component of modern cancer treatment strategies, offering improved survival rates and better quality of life for patients.

Browse 60+ figures and 210+ market data tables and detailed Table of Content on “Cancer Biologics Market” by Distribution by Type of Biologic (Antibodies, Cell and Gene Therapies, Oncolytic Viral Therapies, mRNA Therapies and Vaccines, Nucleotide-based Drugs, Peptides, and Other Biologics), Target Indication (Blood Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Skin Cancer, Renal Cancer, Cervical and Gastric Cancer, Liver Cancer, Bladder Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, Brain Cancer, and Other Type of Cancer) and Geography (North America, Europe, Asia-Pacific and Rest of the World), and Treatment Guidelines and Unmet Needs: Industry Trends and Global Forecasts, till 2035” here: https://www.rootsanalysis.com/reports/cancer-biologics-market.html

Market Drivers

Several factors are propelling the growth of the cancer biologics market. One of the key factors driving the future of the global cancer biologics market is the growing preference for personalized healthcare, wherein treatments (including bispecific antibodies and cell therapies) are tailored to selectively correct the mutated, disease-causing genes of individual patients. Additionally, the rising prevalence of various types of cancer across the world is further driving the cancer biologics market.

Market Restraints

While the cancer biologics market growth is substantial, it is not without its challenges. One of the primary restraints is the stringent regulatory requirements and guidelines of governing bodies, such as the United States Food and Drug Administration (USFDA), Health Canada, and European Commission. The safety and efficacy standards on cancer biologics drugs are often challenging to meet as they require rigorous clinical trials involving diverse patient populations with specific mutated oncogenes. In addition, these therapies are associated with exorbitant development costs compared to conventional therapies, primarily since they are highly personalized and require individualized development as well as manufacturing processes.

Growth Factors

Despite these challenges, several growth factors continue to drive the cancer biologics market forward. The growing investments in research and development of advanced therapies by biotech firms, research institutions, and pharmaceutical companies have been key contributors to market growth. Additionally, several large players are strategically investing in acquiring small oncology companies to strengthen their pipeline of targeted drugs. Owing to these factors, the global cancer biologics market is anticipated to flourish remarkably in the foreseen future.

Cancer Biologics Market Segments

Based on the type of biologic manufactured, the market is segmented into antibodies, cell and gene therapies, oncolytic viral therapies, mRNA therapies and vaccines, nucleotide-based drugs, peptides, and other biologics.

• The antibodies segment is likely to capture the largest revenue share of close to 65% in the cancer biologics market in the current year.
• The mRNA therapies and vaccines segment is anticipated to be the fastest-growing segment in this industry, with an annualized growth rate (CAGR) of 60.2% during the forecast period.

Based on target indication, the market is segmented into blood cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, skin cancer, renal cancer, cervical and gastric cancer, liver cancer, bladder cancer, ovarian cancer, pancreatic cancer, head and neck cancer, brain cancer, and other types of cancer.

• The blood cancer segment is likely to capture the largest revenue share of 20% in the cancer biologics market in the current year.
• The breast cancer segment is anticipated to be the fastest-growing segment in this industry, with an annualized growth rate (CAGR) of 14.0% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World.

• North America is expected to dominate the cancer biologics market, accounting for the largest revenue share of close to 45% in the current year.
• In Asia-Pacific, the cancer biologics market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The cancer biologics market report also includes profiles of key players (listed below) that are engaged in the cancer biologics domain:

• Abbott
• AbbVie
• Amgen
• AstraZeneca
• BioNTech
• Bristol Myers Squibb
• Eli Lilly and Company
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda Pharmaceuticals

You Can Download Free Sample PDF Copy of This Report At: https://www.rootsanalysis.com/reports/cancer-biologics-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables readers to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com